InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-28.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Strobeck Matthew, Director. Director active across 5 companies, notably QUIDEL CORP. In total, 22 reports have been recorded. Breakdown: 7 buys · 0 sell. Total volume traded: €3m. History available since 12 May 2021. The latest transaction was disclosed on 5 November 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations22 total
4,000 shares@ US$1.39790.2% of flowCommon StockSEC:0000905148-24-002950:0
Ideal exit: 2 Aug 2025 (T+270)
2,416 shares0Common StockSEC:0000950170-24-066008:0
52,160 sharesCommon StockSEC:0000905148-24-001615:0
100,000 sharesCommon StockSEC:0001104659-24-006678:0
Ideal exit: 19 Oct 2024 (T+270)
127,777 shares@ US$1.626.0% of flowCommon StockSEC:0000905148-23-000628:0
2,248 shares0Common StockSEC:0001209191-23-035426:0
427 shares0Common StockSEC:0001209191-23-031413:0
875 shares0Common StockSEC:0001209191-23-029932:0
869,565 shares@ US$1.1530.8% of flowCommon StockSEC:0001140361-22-042597:0
Ideal exit: 18 Aug 2023 (T+270)
6,533 sharesCommon StockSEC:0000899243-22-020490:0
6,533 sharesCommon StockSEC:0000899243-22-020410:0
1,624 shares0Common StockSEC:0001209191-22-031194:0
558,659 shares@ US$1.791.70% mcap46.4% of flowCommon StockSEC:0001567619-22-008353:0
Ideal exit: 2 Jan 2023 (T+270)
20,044 sharesCommon StockSEC:0001140361-22-012920:0
138,700 shares@ US$4.350.98% mcap100.0% of flowCommon StockSEC:0001567619-22-000277
Ideal exit: 26 Sept 2022 (T+270)
138,700 shares@ US$4.350.98% mcap26.8% of flowCommon StockSEC:0001567619-22-000277:0
Ideal exit: 26 Sept 2022 (T+270)
19,531 shares@ US$7.6850.0% of flowCommon StockSEC:0001628280-21-024840:0
19,531 shares@ US$7.68100.0% of flowCommon StockSEC:0001628280-21-024840
1,040 shares0Common StockSEC:0001209191-21-032981
1,040 shares0Common StockSEC:0001209191-21-032981:0
20,000 sharesCommon StockSEC:0001144204-16-080228:0
Ideal exit: 5 Nov 2016 (T+270)
12,500 sharesCommon StockSEC:0001179110-16-018063:0
22 of 22 declarations
About Strobeck Matthew
Matthew Strobeck serves as a Board Member at Quidel Corp, Accelerate Diagnostics, Inc, and Biodesix Inc. As a board member, he plays a key role in the governance and strategy of the companies. His expertise is essential for their development.
